Summary:
Gestalt Diagnostics raises $7.5 million to enhance AI tools for digital pathology.
Funding aims to improve cancer detection and faster diagnoses.
Investment will help in expanding customer outreach and pursuing FDA clearance.
CEO Dan Roark emphasizes the importance of PathFlow for real-time collaboration.
Gestalt is part of a growing biotech sector in Washington state.
Gestalt Diagnostics, a healthcare startup based in Spokane, Washington, has successfully raised $7.5 million to enhance its AI tools for digital pathology analysis. This funding aims to improve cancer detection and facilitate real-time collaboration between healthcare providers and pathologists, leading to faster diagnoses.
The investment will bolster efforts to expand customer outreach, enhance AI capabilities, and pursue FDA clearance for its innovative technology. As cancer rates climb and the number of pathologists declines, the need for effective digital analysis technology is more critical than ever.
Dan Roark, CEO of Gestalt, stated, “We’ve already streamlined how pathologists navigate fragmented systems by creating PathFlow, a unified platform for viewing pathology cases digitally and collaborating with leading experts in real-time without the need to ship specimens. Now, we’ll accelerate innovation and scale our reach to meet the growing demands of modern pathology.”
Established in 2017, Gestalt employs a diverse workforce across the country and internationally, with its headquarters in Spokane, which hosts 57 biotech companies according to a recent report by Life Science Washington.
This Series A funding round was led by notable investors including Cowles Ventures, TVF Funds, Inland Imaging Investments, KickStart Funds, and angel investors from the Pacific Northwest. With a total of $13.9 million raised to date, Gestalt is part of a thriving biotech sector in Washington, which has seen substantial investments of $646.17 million across 14 deals in the first quarter of the year.
Comments